Cancer Pharmacologist and HTS Scientist

项目总结： 范德比尔特-英格拉姆癌症中心(VICC)是美国国家癌症研究所指定的综合性癌症中心，拥有超过 270名成员专注于与癌症相关的研究。范德比尔特化学生物学研究所(VICB) 建立了吞吐量筛查(HTS)核心设施，为调查人员提供筛查服务 用于分子探测和药理发现。约书亚·鲍尔博士在界面中扮演着不可或缺的角色 在范德比尔特的癌症研究和化学生物学项目之间。他在…方面有很强的背景 癌症生物学、药理学和生物化学。他的主要目标是使用化学基因组方法， 包括功能基因组学筛选和高含量成像，以识别新的药物靶点并更好地 了解癌细胞如何对治疗做出反应的分子和遗传机制。至 实现这一目标他在HTS设施内与癌症相关的项目集中在三个领域：1)化合物/药物 文库筛选(即HTS)，2)功能基因组学(siRNA/CRISPR)文库筛选，以及3)高含量 筛查(HCS)和分析。到目前为止，鲍尔博士已经为80多人提供了支持和智力贡献 HTS项目，包括与至少41名癌症中心成员的合作，其中包括31名由NCI资助的成员。 这些持续的合作使他能够开发创新的分析方法和新颖的筛选项目 这有助于范德比尔特高温超导核心和癌症研究计划的成功。他的重要角色和 成功源于他构思、协作、设计和执行屏幕的能力，以及智力贡献 向项目、资助提案和手稿提供资助。此外，通过参加各种会议和 研讨会Bauer博士致力于将最先进的技术和想法带到Vanderbilt HTS工厂。这个 他的技能、专业知识和知识的结合为范德比尔特提供了一个独特的角色来修补癌症研究， 化学生物学、基因组学、药物发现和转译药物研究。通过他之前资助的 在荣获R50大奖后，Bauer博士已经进一步推进了他在HTS和他的职业发展方面的重点领域。所以 到目前为止(2016-20)，他已经与人合著了11篇论文，资助了38项与癌症有关的拨款 提议，支持和培训了50多名高温超导仪器或软件的研究生和博士后， 开发了几个新的功能基因组学屏幕(CRISPR和ORFeome)，并开创了几个 用于高含量药物筛选的高通量3D有机物模型。鲍尔博士已经成为 NCI-化学生物学联盟，在那里他接触到了世界级的药物发现专家。最后， 鲍尔博士的工作和合作的结果已经影响了临床试验的设计，发起赞助 研究，并导致了领导分子的进一步发展。因此，鲍尔博士继续担任 癌症药剂师和HTS科学家对癌症研究计划是完全不可或缺的，网址为 范德比尔特。

Project Summary: The Vanderbilt-Ingram Cancer Center (VICC) is an NCI-designated Comprehensive Cancer Center with over 270 members focused on cancer-related research. The Vanderbilt Institute of Chemical Biology (VICB) High- Throughput Screening (HTS) core facility was established to provide screening-based services for investigators for molecular probe and pharmacological discovery. Dr. Joshua Bauer plays an integral role in the interface between the cancer research and chemical biology programs at Vanderbilt. He has a strong background in cancer biology, pharmacology, and biochemistry. His main goal is to use chemical genomic approaches, including functional genomics screening and high-content imaging, to identify novel drug targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics. To achieve this goal his cancer-related projects within the HTS facility are focused on three areas: 1) compound/drug library screening (i.e., HTS), 2) functional genomics (siRNA/CRISPR) library screening, and 3) high-content screening (HCS) and analysis. To date, Dr. Bauer has provided support and intellectual contributions to over 80 HTS projects, including collaborations with at least 41 Cancer Center members, including 31 that are NCI funded. These continued collaborations have allowed him to develop innovative assays and novel screening projects that contribute to the success of the Vanderbilt HTS core and cancer research program. His vital role and success stems from his ability to conceive, collaborate, design and perform screens, and intellectually contribute to projects, grant proposals, and manuscripts. In addition, through participation in conferences, meetings and workshops Dr. Bauer strives to bring state-of-the-art technologies and ideas to the Vanderbilt HTS facility. The blend of his skills, expertise, and knowledge provide a unique role within Vanderbilt to mend cancer research, chemical biology, genomics, drug discovery, and translational drug investigation. Through his previously funded R50 award, Dr. Bauer has already further advanced his areas of focus in HTS and his career development. So far on the award (2016-20), he has been co-authored on 11 papers, has supported 38 cancer-related grant proposals, supported and trained over 50 graduate students and postdocs on HTS instrumentation or software, has developed several novel functional genomics screens (CRISPR and ORFeome), and has pioneered several high-throughput 3D organoid models for high-content drug screening. Dr. Bauer has become a member of the NCI- Chemical Biology Consortium where he has been exposed to world-class drug discovery experts. Finally, the results of Dr. Bauer's work and collaborations have influenced the design of clinical trials, initiated sponsored research, and has led to lead molecules for further development. Therefore, Dr. Bauer's continued role as a Cancer Pharmacologist & HTS Scientist is completely indispensable to the cancer research program at Vanderbilt.